Healthcare Resource Utilization and Costs Associated With Patients Prescribed Afatinib or Erlotinib as First-Line Therapy for EGFR Mutation-Positive NSCLC in the United States

Journal of Medical Economics - United Kingdom
doi 10.1080/13696998.2019.1645681
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Informa UK Limited

Related search

Healthcare Resource Utilization and Associated Costs in Patients With Advanced Melanoma Receiving First-Line Ipilimumab

Journal of Cancer Therapy
2015English

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

Oncotarget
Oncology
2017English

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2015English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Neoplasma
Cancer Research
2013English

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Health Care Resource Utilization and Costs of Patients With Aspergillosis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

PC04.01 Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First Versus Osimertinib First)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy